Depressive syndromes in neurological disorders

  • Julian Hellmann-Regen
  • Dominique Piber
  • Kim Hinkelmann
  • Stefan M. Gold
  • Christoph Heesen
  • Carsten Spitzer
  • Matthias Endres
  • Christian OtteEmail author


Depressive syndromes represent a common and often characteristic feature in a number of neurological disorders. One prominent example is the development of post-stroke depression, which can be observed in more than one-third of stroke survivors in the aftermath of an ischemic stroke. Thus, post-stroke depression represents one of the most prevalent, disabling, and potentially devastating psychiatric post-stroke complications. On the other hand, depressive syndromes may also be considered as a risk factor for certain neurological disorders, as recently revealed by a meta-analysis of prospective cohort studies, which demonstrated an increased risk for ischemic events in depressed patients. Moreover, depressive syndromes represent common comorbidities in a number of other neurological disorders such as Parkinson’s disease, multiple sclerosis, or epilepsy, in which depression has a strong impact on both quality of life and outcome of the primary neurological disorder.


Depression Neuropsychiatry Psychosomatic medicine Neurological disorders 


Conflict of interest

Christian Otte has received honoraria for lectures or scientific advice from Astra Zeneca, Berlin Chemie, Lundbeck, and Servier; and Matthias Endres has received research funding from AstraZeneca and Sanofi and has received honoraria for lectures or scientific advice from AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Desitin, Eisei, Ever, Glaxo Smith Kline, MSD, Novartis, Pfizer, Sanofi, Takeda, and Trommsdorff. The other authors declare that they have no conflict of interest.

This article is part of the supplement “Bridging the gap between Neurobiology and Psychosocial Medicine.” This supplement was not sponsored by outside commercial interests. It was funded by the German Association for Psychiatry and Psychotherapy (DGPPN).


  1. 1.
    (2005) The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 11:328–337Google Scholar
  2. 2.
    Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618PubMedGoogle Scholar
  3. 3.
    Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24:2175–2186PubMedGoogle Scholar
  4. 4.
    Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P (2012) Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47Google Scholar
  5. 5.
    Andrade C (2012) Drug interactions in the treatment of depression in patients with ischemic heart disease. J Clin Psychiatry 73:e1475–e1477PubMedGoogle Scholar
  6. 6.
    Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71:1565–1575PubMedGoogle Scholar
  7. 7.
    Arida RM, Scorza FA, Cavalheiro EA (2010) Favorable effects of physical activity for recovery in temporal lobe epilepsy. Epilepsia 51(Suppl 3):76–79PubMedGoogle Scholar
  8. 8.
    Arida RM, Scorza FA, Gomes da Silva S, Schachter SC, Cavalheiro EA (2010) The potential role of physical exercise in the treatment of epilepsy. Epilepsy Behav 17:432–435PubMedGoogle Scholar
  9. 9.
    Arnett PA, Barwick FH, Beeney JE (2008) Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc 14:691–724PubMedGoogle Scholar
  10. 10.
    Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG (2013) The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke 44:1105–1110PubMedGoogle Scholar
  11. 11.
    Ayerbe L, Ayis S, Wolfe CD, Rudd AG (2013) Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 202:14–21PubMedGoogle Scholar
  12. 12.
    Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. NeuroReport 11:1153–1158PubMedGoogle Scholar
  13. 13.
    Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, Janardhan V, Dubey N, Kinkel PR (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 6:181–185PubMedGoogle Scholar
  14. 14.
    Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMedGoogle Scholar
  15. 15.
    Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, Kanner AM, Caplan R, Plioplys S, Salpekar J, Dunn D, Austin J, Jones J (2008) Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 13(Suppl 1):S1–S29PubMedGoogle Scholar
  16. 16.
    Bartoli F, Lillia N, Lax A, Crocamo C, Mantero V, Carra G, Agostoni E, Clerici M (2013) Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat 2013:862978PubMedGoogle Scholar
  17. 17.
    Bell GS, Sander JW (2009) Suicide and epilepsy. Curr Opin Neurol 22:174–178PubMedGoogle Scholar
  18. 18.
    Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 289:3106–3116PubMedGoogle Scholar
  19. 19.
    Bernardo CG, Singh V, Thompson PM (2008) Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert Opin Drug Saf 7:435–445PubMedGoogle Scholar
  20. 20.
    Boden-Albala B, Litwak E, Elkind MS, Rundek T, Sacco RL (2005) Social isolation and outcomes post stroke. Neurology 64:1888–1892PubMedGoogle Scholar
  21. 21.
    Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 33:219–227PubMedGoogle Scholar
  22. 22.
    Canuet L, Ishii R, Iwase M, Ikezawa K, Kurimoto R, Azechi M, Takahashi H, Nakahachi T, Teshima Y, Takeda M (2009) Factors associated with impaired quality of life in younger and older adults with epilepsy. Epilepsy Res 83:58–65PubMedGoogle Scholar
  23. 23.
    Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, Sharpe M (2000) Depression after stroke and lesion location: a systematic review. Lancet 356:122–126PubMedGoogle Scholar
  24. 24.
    Chaytor N, Ciechanowski P, Miller JW, Fraser R, Russo J, Unutzer J, Gilliam F (2011) Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav 20:545–549PubMedGoogle Scholar
  25. 25.
    Chen C, Leys D, Esquenazi A (2013) The interaction between neuropsychological and motor deficits in patients after stroke. Neurology 80:S27–S34PubMedGoogle Scholar
  26. 26.
    Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMedGoogle Scholar
  27. 27.
    Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I (2011) Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 10:123–130PubMedGoogle Scholar
  28. 28.
    Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E (2007) Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 6:693–698PubMedGoogle Scholar
  29. 29.
    Ciechanowski P, Chaytor N, Miller J, Fraser R, Russo J, Unutzer J, Gilliam F (2010) PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 19:225–231PubMedGoogle Scholar
  30. 30.
    Cook MJ, O’Brien TJ, Berkovic SF, Murphy M, Morokoff A, Fabinyi G, D’Souza W, Yerra R, Archer J, Litewka L, Hosking S, Lightfoot P, Ruedebusch V, Sheffield WD, Snyder D, Leyde K, Himes D (2013) Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 12:563–571PubMedGoogle Scholar
  31. 31.
    Cotterman-Hart S (2010) Depression in epilepsy: why aren’t we treating? Epilepsy Behav 19:419–421PubMedGoogle Scholar
  32. 32.
    Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L (1996) Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27:1211–1214PubMedGoogle Scholar
  33. 33.
    Danzer SC (2012) Depression, stress, epilepsy and adult neurogenesis. Exp Neurol 233:22–32PubMedGoogle Scholar
  34. 34.
    de Abajo FJ, Montero D, Rodriguez LA, Madurga M (2006) Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 98:304–310PubMedGoogle Scholar
  35. 35.
    de Man-van Ginkel JM, Hafsteinsdottir TB, Lindeman E, Ettema RG, Grobbee DE, Schuurmans MJ (2013) In-Hospital Risk Prediction for Post-stroke depression: development and validation of the Post-stroke depression prediction scale. Stroke 44:2441–2445PubMedGoogle Scholar
  36. 36.
    DiIorio C, Shafer PO, Letz R, Henry TR, Schomer DL, Yeager K (2004) Project EASE: a study to test a psychosocial model of epilepsy medication management. Epilepsy Behav 5:926–936PubMedGoogle Scholar
  37. 37.
    Dobkin RD, Allen LA, Menza M (2007) Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord 22:946–952PubMedGoogle Scholar
  38. 38.
    Dong JY, Zhang YH, Tong J, Qin LQ (2012) Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 43:32–37PubMedGoogle Scholar
  39. 39.
    Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA (2011) Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 168:913–920PubMedGoogle Scholar
  40. 40.
    Ekinci O, Titus JB, Rodopman AA, Berkem M, Trevathan E (2009) Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. Epilepsy Behav 14:8–18PubMedGoogle Scholar
  41. 41.
    Farabaugh A, Locascio JJ, Yap L, Growdon J, Fava M, Crawford C, Matthews J, McCutchen J, Buchin J, Pava J, Alpert JE (2010) Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics 51:124–129PubMedGoogle Scholar
  42. 42.
    Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, Hennerici M (1998) Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 55:66–72PubMedGoogle Scholar
  43. 43.
    Feinstein A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology 59:674–678PubMedGoogle Scholar
  44. 44.
    Feinstein A (2011) Multiple sclerosis and depression. Mult Scler 17:1276–1281PubMedGoogle Scholar
  45. 45.
    Feinstein A, O’Connor P, Akbar N, Moradzadeh L, Scott CJ, Lobaugh NJ (2010) Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler 16:189–196PubMedGoogle Scholar
  46. 46.
    Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62:586–590PubMedGoogle Scholar
  47. 47.
    Fischer A, Otte C, Krieger T, Nicholls RA, Kruger S, Ziegler KJ, Schulz KH, Heesen C, Gold SM (2012) Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression. Psychoneuroendocrinology 37:1712–1718PubMedGoogle Scholar
  48. 48.
    Folstein MF, Maiberger R, McHugh PR (1977) Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 40:1018–1020PubMedGoogle Scholar
  49. 49.
    Frisina PG, Tenenbaum HR, Borod JC, Foldi NS (2008) The effects of antidepressants in Parkinson’s disease: a meta-analysis. Int J Neurosci 118:667–682PubMedGoogle Scholar
  50. 50.
    Fuller-Thomson E, Brennenstuhl S (2009) The association between depression and epilepsy in a nationally representative sample. Epilepsia 50:1051–1058PubMedGoogle Scholar
  51. 51.
    Gehi A, Haas D, Pipkin S, Whooley MA (2005) Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 165:2508–2513PubMedGoogle Scholar
  52. 52.
    Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McLvor M (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709PubMedGoogle Scholar
  53. 53.
    Gold SM, Kern KC, O’Connor MF, Montag MJ, Kim A, Yoo YS, Giesser BS, Sicotte NL (2010) Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 68:553–559PubMedGoogle Scholar
  54. 54.
    Gold SM, Kruger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, Heesen C (2011) Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry 82:814–818PubMedGoogle Scholar
  55. 55.
    Gold SM, O’Connor MF, Gill R, Kern KC, Shi Y, Henry RG, Pelletier D, Mohr DC, Sicotte NL (2012) Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp. doi: 10.1002/hbm.22154
  56. 56.
    Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:517–584PubMedGoogle Scholar
  57. 57.
    Grossman P, Kappos L, Gensicke H, D’Souza M, Mohr DC, Penner IK, Steiner C (2010) MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 75:1141–1149PubMedGoogle Scholar
  58. 58.
    Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K (2011) Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: secondary prevention in uppsala primary health care project (SUPRIM). Arch Intern Med 171:134–140PubMedGoogle Scholar
  59. 59.
    Haase CG, Lienemann M, Faustmann PM (2008) Neuropsychological deficits but not coping strategies are related to physical disability in multiple sclerosis. Eur Arch Psychiatry Clin Neurosci 258:35–39PubMedGoogle Scholar
  60. 60.
    Hackam DG, Mrkobrada M (2012) Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 79:1862–1865PubMedGoogle Scholar
  61. 61.
    Hackett ML, Anderson CS, House A, Halteh C (2008) Interventions for preventing depression after stroke. Cochrane Database Syst Rev: CD003689Google Scholar
  62. 62.
    Hackett ML, Anderson CS, House A, Xia J (2008) Interventions for treating depression after stroke. Cochrane Database Syst Rev: CD003437Google Scholar
  63. 63.
    Hackett ML, Anderson CS, House AO (2005) Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36:1098–1103PubMedGoogle Scholar
  64. 64.
    Hama S, Yamashita H, Shigenobu M, Watanabe A, Kurisu K, Yamawaki S, Kitaoka T (2007) Post-stroke affective or apathetic depression and lesion location: left frontal lobe and bilateral basal ganglia. Eur Arch Psychiatry Clin Neurosci 257:149–152PubMedGoogle Scholar
  65. 65.
    Hamer M, David Batty G, Seldenrijk A, Kivimaki M (2011) Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 32:437–442PubMedGoogle Scholar
  66. 66.
    Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 170:205–228PubMedGoogle Scholar
  67. 67.
    Harter M, Klesse C, Bermejo I, Bschor T, Gensichen J, Harfst T, Hautzinger M, Kolada C, Kopp I, Kuhner C, Lelgemann M, Matzat J, Meyerrose B, Mundt C, Niebling W, Ollenschlager G, Richter R, Schauenburg H, Schulz H, Weinbrenner S, Schneider F, Berger M (2010) Evidence-based therapy of depression: S3 guidelines on unipolar depression. Nervenarzt 81:1049–1068PubMedGoogle Scholar
  68. 68.
    Hermann BP, Trenerry MR, Colligan RC (1996) Learned helplessness, attributional style, and depression in epilepsy. Bozeman Epilepsy Surgery Consortium. Epilepsia 37:680–686PubMedGoogle Scholar
  69. 69.
    Hesdorffer DC, Lee P (2009) Health, wealth, and culture as predominant factors in psychosocial morbidity. Epilepsy Behav 15(Suppl 1):S36–S40PubMedGoogle Scholar
  70. 70.
    Heuschmann P, Busse O, Wagner M, Endres M, Villringer A, Röther J, Kolominsky-Rabas P, Berger K (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Für das Kompetenznetz Schlaganfall, die Deutsche Schlaganfall Gesellschaft sowie die Stiftung Deutsche Schlaganfall-Hilfe. Akt Neurol 37:333–340Google Scholar
  71. 71.
    Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61(81–109):C101–C111Google Scholar
  72. 72.
    Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, Kortelainen ML, Huikuri HV (2012) Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 33:745–751PubMedGoogle Scholar
  73. 73.
    Hoppe C, Elger CE (2011) Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 7:462–472PubMedGoogle Scholar
  74. 74.
    Huff W, Steckel R, Sitzer M (2003) Poststroke depression: risk factors and effects on the course of the stroke. Nervenarzt 74:104–114PubMedGoogle Scholar
  75. 75.
    Hughes JR (2010) Periodic lateralized epileptiform discharges: do they represent an ictal pattern requiring treatment? Epilepsy Behav 18:162–165PubMedGoogle Scholar
  76. 76.
    Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 113:211–220PubMedGoogle Scholar
  77. 77.
    Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, Lieb R (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 34:597–611PubMedGoogle Scholar
  78. 78.
    Jensen FE (2011) Epilepsy as a spectrum disorder: Implications from novel clinical and basic neuroscience. Epilepsia 52(Suppl 1):1–6PubMedGoogle Scholar
  79. 79.
    Kanner AM (2011) Depression and epilepsy: a bidirectional relation? Epilepsia 52(Suppl 1):21–27PubMedGoogle Scholar
  80. 80.
    Kanner AM, Trimble M, Schmitz B (2010) Postictal affective episodes. Epilepsy Behav 19:156–158PubMedGoogle Scholar
  81. 81.
    Kern S, Schultheiss T, Schneider H, Schrempf W, Reichmann H, Ziemssen T (2011) Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology 36:1505–1512PubMedGoogle Scholar
  82. 82.
    Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281PubMedGoogle Scholar
  83. 83.
    Kiy G, Lehmann P, Hahn HK, Eling P, Kastrup A, Hildebrandt H (2011) Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler 17:1088–1097PubMedGoogle Scholar
  84. 84.
    Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J (2011) Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev: CD007295Google Scholar
  85. 85.
    Kronenberg G, Balkaya M, Prinz V, Gertz K, Ji S, Kirste I, Heuser I, Kampmann B, Hellmann-Regen J, Gass P, Sohr R, Hellweg R, Waeber C, Juckel G, Hortnagl H, Stumm R, Endres M (2012) Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry 72:273–281PubMedGoogle Scholar
  86. 86.
    Kronenberg G, Katchanov J, Endres M (2006) Post-stroke depression: clinical aspects, epidemiology, therapy, and pathophysiology. Nervenarzt 77:1176, 1179–1182, 1184–1175Google Scholar
  87. 87.
    Lange-Asschenfeldt C, Lederbogen F (2011) Antidepressant therapy in coronary artery disease. Nervenarzt 82:657–664; quiz 665–656PubMedGoogle Scholar
  88. 88.
    Lederbogen F, Baranyai R, Gilles M, Menart-Houtermans B, Tschoepe D, Deuschle M (2004) Effect of mental and physical stress on platelet activation markers in depressed patients and healthy subjects: a pilot study. Psychiatry Res 127:55–64PubMedGoogle Scholar
  89. 89.
    Lee YC, Shau WY, Chang CH, Chen ST, Lin MS, Lai MS (2012) Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients: a nationwide cohort study in Taiwan. J Clin Psychopharmacol 32:518–524PubMedGoogle Scholar
  90. 90.
    Leung M, Shore R (1996) Fluvoxamine-associated bleeding. Can J Psychiatry 41:604–605PubMedGoogle Scholar
  91. 91.
    Lewis AJ (1934) Melancholia: a historical review. J Ment Sci 80:1–42Google Scholar
  92. 92.
    Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES (2008) Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118:1768–1775PubMedGoogle Scholar
  93. 93.
    Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L, Popa-Wagner A (2012) Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 16:1961–1969PubMedGoogle Scholar
  94. 94.
    Lundgren T, Dahl J, Hayes SC (2008) Evaluation of mediators of change in the treatment of epilepsy with acceptance and commitment therapy. J Behav Med 31:225–235PubMedGoogle Scholar
  95. 95.
    Lundgren T, Dahl J, Yardi N, Melin L (2008) Acceptance and Commitment Therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. Epilepsy Behav 13:102–108PubMedGoogle Scholar
  96. 96.
    Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264–271PubMedGoogle Scholar
  97. 97.
    Martinovic Z, Simonovic P, Djokic R (2006) Preventing depression in adolescents with epilepsy. Epilepsy Behav 9:619–624PubMedGoogle Scholar
  98. 98.
    Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442PubMedGoogle Scholar
  99. 99.
    Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML (2012) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 11: CD009286Google Scholar
  100. 100.
    Mensah SA, Beavis JM, Thapar AK, Kerr MP (2007) A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav 11:118–124PubMedGoogle Scholar
  101. 101.
    Micallef S, Spooner CG, Harvey AS, Wrennall JA, Wilson SJ (2010) Psychological outcome profiles in childhood-onset temporal lobe epilepsy. Epilepsia 51:2066–2073PubMedGoogle Scholar
  102. 102.
    Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741PubMedGoogle Scholar
  103. 103.
    Miller JM, Kustra RP, Vuong A, Hammer AE, Messenheimer JA (2008) Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 68:1493–1509PubMedGoogle Scholar
  104. 104.
    Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, Tirschwell D, Teri L (2009) Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke 40:3073–3078PubMedGoogle Scholar
  105. 105.
    Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, Tasch ET (2005) Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 62:1007–1014PubMedGoogle Scholar
  106. 106.
    Moller A, Wiedemann G, Rohde U, Backmund H, Sonntag A (1994) Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 89:117–121PubMedGoogle Scholar
  107. 107.
    Morris PL, Robinson RG, Andrzejewski P, Samuels J, Price TR (1993) Association of depression with 10-year poststroke mortality. Am J Psychiatry 150:124–129PubMedGoogle Scholar
  108. 108.
    Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79:1027–1031PubMedGoogle Scholar
  109. 109.
    Mula M, Monaco F (2009) Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 11:1–9PubMedGoogle Scholar
  110. 110.
    Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR (2009) Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 5:533–541PubMedGoogle Scholar
  111. 111.
    Nelva A, Guy C, Tardy-Poncet B, Beyens MN, Ratrema M, Benedetti C, Ollagnier M (2000) Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants. Seven case reports and review of the literature. Rev Med Interne 21:152–160PubMedGoogle Scholar
  112. 112.
    Neu P (2009) Correlation of depression with stroke. Pathophysiological mechanisms. Nervenarzt 80(772):774–776, 778–780Google Scholar
  113. 113.
    Niedermaier N, Bohrer E, Schulte K, Schlattmann P, Heuser I (2004) Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 65:1619–1623PubMedGoogle Scholar
  114. 114.
    Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG (1997) Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38:1062–1068PubMedGoogle Scholar
  115. 115.
    O’Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR (2008) Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 168:2232–2237PubMedGoogle Scholar
  116. 116.
    O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376:112–123PubMedGoogle Scholar
  117. 117.
    Otte C, Marmar CR, Pipkin SS, Moos R, Browner WS, Whooley MA (2004) Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 56:241–247PubMedGoogle Scholar
  118. 118.
    Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA (2005) Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 162:2139–2145PubMedGoogle Scholar
  119. 119.
    Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB (2011) Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 306:1241–1249PubMedGoogle Scholar
  120. 120.
    Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F (2001) Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 50:718–729PubMedGoogle Scholar
  121. 121.
    Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (2003) Major depression in multiple sclerosis: a population-based perspective. Neurology 61:1524–1527PubMedGoogle Scholar
  122. 122.
    Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ (2012) Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson’s disease. Mov Disord 27:880–887PubMedGoogle Scholar
  123. 123.
    Piber D, Hinkelmann K, Gold SM, Heesen C, Spitzer C, Endres M, Otte C (2012) Depression and neurological diseases. Nervenarzt 83:1423–1433PubMedGoogle Scholar
  124. 124.
    Pollak Y, Orion E, Goshen I, Ovadia H, Yirmiya R (2002) Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of ‘depression due to multiple sclerosis’. Brain Behav Immun 16:533–543PubMedGoogle Scholar
  125. 125.
    Pollak Y, Ovadia H, Orion E, Yirmiya R (2003) The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J Neuroimmunol 137:100–108PubMedGoogle Scholar
  126. 126.
    Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189; quiz 313PubMedGoogle Scholar
  127. 127.
    Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedGoogle Scholar
  128. 128.
    Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229–1236PubMedGoogle Scholar
  129. 129.
    Riedel O, Dodel R, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Wittchen HU (2011) Dementia and depression determine care dependency in Parkinson’s disease: analysis of 1,449 outpatients receiving nursing care in Germany. Nervenarzt 82:1012–1019PubMedGoogle Scholar
  130. 130.
    Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S (2008) Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299:2391–2400PubMedGoogle Scholar
  131. 131.
    Robinson RG, Spalletta G (2010) Poststroke depression: a review. Can J Psychiatry 55:341–349PubMedGoogle Scholar
  132. 132.
    Salter KL, Foley NC, Zhu L, Jutai JW, Teasell RW (2012) Prevention of Poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis [Epub ahead of print]Google Scholar
  133. 133.
    Schiffer RB, Wineman NM, Weitkamp LR (1986) Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 143:94–95PubMedGoogle Scholar
  134. 134.
    Schwarz J, Odin P, Buhmann C, Csoti I, Jost W, Wullner U, Storch A (2011) Depression in Parkinson’s disease. J Neurol 258:S336–S338PubMedGoogle Scholar
  135. 135.
    Schweiger U, Greggersen W, Rudolf S, Pusch M, Menzel T, Winn S, Hassfurth J, Fassbinder E, Kahl KG, Oltmanns KM, Hohagen F, Peters A (2008) Disturbed glucose disposal in patients with major depression; application of the glucose clamp technique. Psychosom Med 70:170–176PubMedGoogle Scholar
  136. 136.
    Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80PubMedGoogle Scholar
  137. 137.
    Siegert RJ, Abernethy DA (2005) Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76:469–475PubMedGoogle Scholar
  138. 138.
    Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J (2008) Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 164:274–282PubMedGoogle Scholar
  139. 139.
    Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10:49PubMedGoogle Scholar
  140. 140.
    Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, Rosal MC, Wenger NK, Wassertheil-Smoller S (2009) Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 169:2128–2139PubMedGoogle Scholar
  141. 141.
    Sperling MR, Schilling CA, Glosser D, Tracy JI, Asadi-Pooya AA (2008) Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. Seizure 17:302–307PubMedGoogle Scholar
  142. 142.
    Stenager EN, Koch-Henriksen N, Stenager E (1996) Risk factors for suicide in multiple sclerosis. Psychother Psychosom 65:86–90PubMedGoogle Scholar
  143. 143.
    Stenager EN, Stenager E, Koch-Henriksen N, Bronnum-Hansen H, Hyllested K, Jensen K, Bille-Brahe U (1992) Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 55:542–545PubMedGoogle Scholar
  144. 144.
    Strubel T, Birkhofer A, Mossmer G, Forstl H (2010) SSRI—treatment and bleeding. What risks do we take? Nervenarzt 81:549–555PubMedGoogle Scholar
  145. 145.
    Sullivan MJ, Weinshenker B, Mikail S, Edgley K (1995) Depression before and after diagnosis of multiple sclerosis. Mult Scler 1:104–108PubMedGoogle Scholar
  146. 146.
    Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J (2009) Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 104:1475–1482PubMedGoogle Scholar
  147. 147.
    Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792–798PubMedGoogle Scholar
  148. 148.
    The IFNB Multiple Sclerosis Study Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 47:889–894Google Scholar
  149. 149.
    Thompson NJ, Walker ER, Obolensky N, Winning A, Barmon C, Diiorio C, Compton MT (2010) Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav 19:247–254PubMedGoogle Scholar
  150. 150.
    Thorndike AN, Regan S, McKool K, Pasternak RC, Swartz S, Torres-Finnerty N, Rigotti NA (2008) Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med 168:186–191PubMedGoogle Scholar
  151. 151.
    Wagner JL, Smith G, Ferguson P, van Bakergem K, Hrisko S (2010) Pilot study of an integrated cognitive-behavioral and self-management intervention for youth with epilepsy and caregivers: coping Openly and Personally with Epilepsy (COPE). Epilepsy Behav 18:280–285PubMedGoogle Scholar
  152. 152.
    Wagner JL, Smith G, Ferguson PL, Horton S, Wilson E (2009) A hopelessness model of depressive symptoms in youth with epilepsy. J Pediatr Psychol 34:89–96PubMedGoogle Scholar
  153. 153.
    Walker ER, Obolensky N, Dini S, Thompson NJ (2010) Formative and process evaluations of a cognitive-behavioral therapy and mindfulness intervention for people with epilepsy and depression. Epilepsy Behav 19:239–246PubMedGoogle Scholar
  154. 154.
    Weintraub D, Burn DJ (2011) Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 26:1022–1031PubMedGoogle Scholar
  155. 155.
    Whooley MA (2006) Depression and cardiovascular disease: healing the broken-hearted. JAMA 295:2874–2881PubMedGoogle Scholar
  156. 156.
    Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS (2008) Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300:2379–2388PubMedGoogle Scholar
  157. 157.
    Whyte EM, Mulsant BH (2002) Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 52:253–264PubMedGoogle Scholar
  158. 158.
    Win S, Parakh K, Eze-Nliam CM, Gottdiener JS, Kop WJ, Ziegelstein RC (2011) Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the Cardiovascular Health Study. Heart 97:500–505PubMedGoogle Scholar
  159. 159.
    Wittchen H, Müller N, Schmidtkunz B, Winter S, Pfister H (2000) Erscheinungsformen, Häufigkeit und Versorgung von Depressionen. Ergebnisse des bundesweiten Gesundheitssurveys “Psychische Störungen”. Fortschr Med Sonderheft I:4–9Google Scholar
  160. 160.
    Wu CS, Wang SC, Cheng YC, Gau SS (2011) Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 168:511–521PubMedGoogle Scholar
  161. 161.
    Zedlitz AM, Rietveld TC, Geurts AC, Fasotti L (2012) Cognitive and graded activity training can alleviate persistent fatigue after stroke: a randomized, controlled trial. Stroke 43:1046–1051PubMedGoogle Scholar
  162. 162.
    Zittel S, Weiller C, Liepert J (2008) Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 22:311–314PubMedGoogle Scholar
  163. 163.
    Zorzon M, de Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, Bratina A, Zivadinov R (2001) Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 248:416–421PubMedGoogle Scholar
  164. 164.
    Zorzon M, Zivadinov R, Nasuelli D, Ukmar M, Bratina A, Tommasi MA, Mucelli RP, Brnabic-Razmilic O, Grop A, Bonfigli L, Cazzato G (2002) Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 9:491–496PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Julian Hellmann-Regen
    • 1
  • Dominique Piber
    • 1
  • Kim Hinkelmann
    • 1
  • Stefan M. Gold
    • 2
  • Christoph Heesen
    • 3
  • Carsten Spitzer
    • 4
  • Matthias Endres
    • 5
    • 6
    • 7
  • Christian Otte
    • 1
    • 7
    Email author
  1. 1.Klinik für Psychiatrie und PsychotherapieCharité Universitätsmedizin BerlinBerlinGermany
  2. 2.Zentrum für Molekulare NeurobiologieUniversitätsklinikum Hamburg-EppendorfHamburgGermany
  3. 3.Klinik für NeurologieUniversitätsklinikum Hamburg-EppendorfHamburgGermany
  4. 4.Asklepios Fachklinikum TiefenbrunnRosdorfGermany
  5. 5.Klinik für NeurologieCharité Universitätsmedizin BerlinBerlinGermany
  6. 6.Centrum für Schlaganfallforschung BerlinCharité Universitätsmedizin BerlinBerlinGermany
  7. 7.ExzellenzCluster NeuroCureCharité Universitätsmedizin BerlinBerlinGermany

Personalised recommendations